For instance, those patients with advanced or metastatic BC harboring FGFR3 mutations in their primary tumor are already being treated with the Food and Drug Administration (FDA)-approved drug Erdafitinib® (NCT05316155), a fibroblast growth factor receptor (FGFR) kinase inhibitor (23). Here, FGFR3 is linked to neoplasm.